Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy
October 13, 2022 16:05 ET
|
Travere Therapeutics, Inc.
Conference call and webcast to be held at 4:30p.m. ET SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that following late-cycle review...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 11, 2022 17:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on October 10, 2022, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 14, 2022 17:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on September 10, 2022, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium
August 25, 2022 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present a genetic evaluation and an analysis of...
Travere Therapeutics and CSL Vifor Announce EMA has Accepted for Review the Conditional Marketing Authorization Application for Sparsentan for the Treatment of IgA Nephropathy
August 22, 2022 07:00 ET
|
Travere Therapeutics, Inc.
A review decision by the European Medicines Agency (EMA) is expected in the second half of 2023 If approved, sparsentan will be a first-in-class treatment to address the significant unmet medical...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 11, 2022 17:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on August 10, 2022, the Compensation Committee of its Board of Directors granted...
Travere Therapeutics Reports Second Quarter 2022 Financial Results
August 04, 2022 07:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its second quarter 2022 financial results and provided a corporate update. New Drug Application...
Travere Therapeutics Provides Regulatory Updates on its Development Programs
August 03, 2022 16:05 ET
|
Travere Therapeutics, Inc.
PDUFA target action date for NDA for sparsentan in IgAN on-track for November 17, 2022 Company to utilize traditional approval process for sparsentan in FSGS following completion of the pivotal Phase...
Travere Therapeutics to Report Second Quarter 2022 Financial Results
July 28, 2022 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, July 28, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2022 financial results on Thursday, August 4, 2022 before the...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 12, 2022 17:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on July 10, 2022, the Compensation Committee of its Board of Directors granted...